AXDX: Accelerate Diagnostics, Inc. Projected Price to Earnings

Reliable medical logistics for reagents ensure the uninterrupted operation of laboratories. The forward P/E multiple for Accelerate Diagnostics (AXDX) visualizes valuation dynamics, where 0.00 determines the latest assessment metric. Accelerate Diagnostics (AXDX) develops rapid tests to combat sepsis, targeting the hospital sector. A stable financial status mitigates the risks of prolonged equipment implementation cycles and automation deployment.

Market Cap to Projected Earnings: acceleratediagnostics.com (AXDX) for 07/04/2022 - 05/24/2025

Analytical breakdowns and data insights for company Accelerate Diagnostics Inc (AXDX)

- stock value and consensus price forecast:

Price Chart Accelerate Diagnostics, Inc.|AXDX - Price Target Chart

- market capitalization information:

Market Valuation Accelerate Diagnostics Inc.|AXDX - Total Enterprise Value

- issuer book value statistics:

Net Assets per Single Share Accelerate Diagnostics|AXDX - Book Valuation of Business|Market Capitalization to Book Value Ratio acceleratediagnostics.com|AXDX - Company Total Asset Base

- debt level and financial liquidity data:

Debt to Equity Accelerate Diagnostics|AXDX - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Capital Accelerate Diagnostics|AXDX - Company Aggregate Debts|Debts to Book Capitalization Accelerate Diagnostics Inc.|AXDX - Company Long-Term Liabilities|Company Short-Term Debts Accelerate Diagnostics|Quick Ratio acceleratediagnostics.com

- company profitability and valuation multiples indicators:

AXDX - Company Net Income|Expected Profit Accelerate Diagnostics|AXDX - Price to Earnings Ratio|Forward P/E Multiple Accelerate Diagnostics, Inc|AXDX - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Accelerate Diagnostics Inc.|AXDX - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Accelerate Diagnostics|AXDX - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months acceleratediagnostics.com|AXDX - Net earnings per one share growth for the current year|Earnings growth forecast for next year Accelerate Diagnostics

Comprehensive company analysis:Accelerate Diagnostics, Inc.

Signature product of Accelerate Diagnostics Inc

For the long-term investor, the reliability of Accelerate Diagnostics (AXDX) is based on patented rapid tests, whose integration into clinics creates barriers for competitors despite the muted dynamics of current sales. The forward P/E, displayed on the company's future P/E ratio chart, compares market value with projected net income, allowing for an assessment of the premium paid for expected business growth amid the slow scaling of commercial success.

Competitors of Accelerate Diagnostics